PGxAI has joined forces with Riyadh-based Najashi Holding to introduce its AI-driven pharmacogenomics platform to Saudi Arabia. The collaboration supports the Kingdom’s healthcare transformation under Vision 2030, reinforcing its position as a global leader in precision medicine.
As part of the partnership, Najashi Holding, a leading regional healthcare investor, will commit equity to PGxAI’s planned $20 million Series A round in 2026. The company will also leverage its extensive public- and private-sector networks to accelerate the adoption of personalized care nationwide.
The joint initiative aims to deploy PGxAI’s technology within Saudi Arabia’s healthcare infrastructure, enabling personalized drug selection, minimizing adverse reactions, and optimizing treatment strategies. By combining genomics with digital health initiatives, the collaboration will expand patient access to precision care and support the Kingdom’s shift toward a data-driven healthcare system.
“Partnering with Najashi Holding aligns with our mission to expand AI-powered pharmacogenomics into new global markets,” said Dr. Mike Zack, co-founder and CEO of PGxAI. “Saudi Arabia’s bold healthcare agenda presents a unique opportunity to integrate precision medicine and harness diverse genetic data at scale. Together, we are committed to advancing ultra-precision care through AI and real-world data, while building sustainable in-country expertise that ensures lasting impact on patient care.”
“Saudi Arabia is moving decisively to embed precision medicine into routine care, and Najashi Holding’s public-private network is the right catalyst to make this possible at scale,” said Allan Gobbs, executive chairman and co-founder of PGxAI. “Together, we will localize PGxAI’s pharmacogenomics platform, integrate with leading health systems and diagnostic labs, and develop in-country capabilities to transform care delivery, improve population health, lower costs, and establish the Kingdom as a global benchmark in innovative and preventive healthcare.”
Also Read
“We are excited to partner with PGxAI,” said Dr. Ibrahim Najashi, chairman of Najashi Holding. “By combining its pharmacogenomics platform with our local expertise and networks, we will accelerate the adoption of personalized medicine and improve outcomes in Saudi Arabia, fully aligned with Vision 2030’s commitment to healthcare innovation.”
The initiative will also contribute to Saudi Arabia’s Health Sector Transformation Program by enhancing clinical decision-making through digital platforms and utilizing large-scale genomic data from the Saudi Genome Program to guide population-level treatment strategies.
This partnership underscores the Kingdom’s commitment to building a world-class, preventive, and precision-based healthcare system, positioning Saudi Arabia at the forefront of global medical innovation.
